Durvalumab and Tremelimumab With or Without High or Low-Dose Radiation Therapy in Treating Patients With Metastatic Colorectal or Non-small Cell Lung Cancer
第2相
実施中（募集終了）
NCT02888743
| 対象疾患 | Metastatic Colorectal Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Stage IV Colorectal Cancer AJCC v7, Stage IV Lung Non-Small Cell Cancer AJCC v7 |
|---|
| 相 | 第2相 |
|---|
| スポンサー | National Cancer Institute (NCI) |
|---|
| ステータス | 実施中（募集終了） |
|---|
| 参加者数 | 110 名 |
|---|
| 介入（薬剤） | Durvalumab, Radiation Therapy, Tremelimumab |
|---|
| 開始日 | 2017年8月14日 |
|---|
| 完了日 | 2023年12月31日 |
|---|
| 結果公開日 | 2024年6月25日 |
|---|
概要
This randomized phase II trial studies the side effects of durvalumab and tremelimumab and to see how well they work with or without high or low-dose radiation therapy in treating patients with colorectal or non-small cell lung cancer that has spread to other parts of the body (metastatic). Immunotherapy with durvalumab and tremelimumab, may induce changes in body's immune system and may interfere with the ability of tumor cells to grow and spread. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Giving durvalumab and tremelimumab with radiation therapy may work better in treating patients with colorectal or non-small cell lung cancer.
Overall Response Rate
Up to 2 years · Participants
| NSCLC Arm A (Tremelimumab, Durvalumab, HD-RT) | 3 Participants |
|---|
| NSCLC Arm B (Tremelimumab, Durvalumab, LD-RT) | 2 Participants |
|---|
| NSCLC Arm C (Tremelimumab, Durvalumab) | 3 Participants |
|---|
| CRC Arm A (Tremelimumab, Durvalumab, HD-RT) | 0 Participants |
|---|
| CRC Arm B (Tremelimumab, Durvalumab, LD-RT) | 0 Participants |
|---|
| p-value | 0.99 |
|---|
| Difference between proportions | 0.0 (95% CI -14.6–14.6) |
|---|
BENITIONS で見る
ClinicalTrials.gov の原文を見る
同じ疾患の他の治験
すべての治験
このページは ClinicalTrials.gov の公開データをまとめたものです。医学的助言ではなく、投資助言でもありません。必ず専門医にご相談ください。